About the Company
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARCT News
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s ...
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.25, a high estimate of $87.00, ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
March 7, 2024 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were ...
Arcturus Therapeutics Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company ...
Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments
Operating Expenses: Increased to $245.0 million in 2023 from $193.8 million in 2022. Net Loss: Reported a net loss of $26.6 ...
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
Greetings and welcome to the Arcturus Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s growth of 10.5%. Last month, the European Commission granted orphan ...
Arcturus Therapeutics Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call
Neda Safarzadeh; VP of IR, Public Relations, and Marketing; Arcturus Therapeutics Holdings, Inc. Joe Payne; President and CEO; Arcturus Therapeutics Holdings, Inc ...
Loading the latest forecasts...